Kolexia
Floquet Anne Oncologie médicale
Floquet Anne
Oncologie médicale
Institut Bergonié
Bordeaux, France
274 Activités
74 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Sarcomes Tumeurs de l'endomètre Tumeurs de l'utérus Léiomyosarcome Tumeurs de la trompe de Fallope

Collaborateurs

Voir plus
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
GSK
11 collaboration(s)
Dernière en 2022
AstraZeneca
9 collaboration(s)
Dernière en 2022
PUBLICLIN
6 collaboration(s)
Dernière en 2021
MSD
5 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
SOLO-1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Essai Clinique (AstraZeneca)   28 février 2024
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma: A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   05 février 2024
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.
Frontiers in oncology   11 janvier 2024
TAPAZ: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Essai Clinique (Novartis)   05 septembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
BFR-ESS: Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Essai Clinique (Centre Léon-Bérard)   31 août 2023
Market opportunities seizing capability and fish farming firm performance: A dynamic managerial capability perspective.
Heliyon   09 août 2023
ARIEL3: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Essai Clinique (pharmaand GmbH)   07 juin 2023